Not a good buy right now: pre-market is sharply lower (-10.53% to 1.19) while the broader market is slightly up, signaling asset-specific weakness.
Trend remains bearish (SMA_200 > SMA_20 > SMA_5); the stock is still trading under long-term downtrend conditions.
With no proprietary buy signals today and weak fundamentals (revenue effectively zero, large losses, EPS collapse), the risk/reward is unattractive for an impatient buyer.
Best stance now is to avoid new buys and wait for a technical reclaim above the pivot (1.251) and/or clearer fundamental catalyst (earnings on 2026-02-12).
Pre-market price 1.19 is below the pivot (1.251), indicating weak near-term momentum; downside risk toward S1 (1.091) and S2 (0.992).
Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), consistent with a prevailing downtrend.
MACD histogram is positive and expanding (0.00954), suggesting a short-term attempt to stabilize/bounce, but it is not strong enough to override the bearish MA structure.
RSI_6 at ~62.9 is neutral-to-slightly warm; not oversold, so there isn’t a clear “forced bounce” setup.
Pattern-based forward stats imply limited near-term upside (+0.71% next week) and a negative 1-month expectation (-8.39%), aligning with a cautious stance.
Positive Catalysts
MACD improving (positive and expanding) can support a short-term bounce if price reclaims the pivot (1.251).
Upcoming earnings event (2026-02-12 after hours) could serve as a catalyst if results or guidance surprise positively.
No notable recent insider selling or hedge fund pressure indicated (both described as neutral).
Neutral/Negative Catalysts
and 1.511 (R2).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: reported as 0 (0.00% YoY), indicating no meaningful operating growth signal from topline.
Net income: -7.118M (improved ~10.17% YoY but still deeply negative), so profitability remains materially weak.
EPS: -13.16, down -98.52% YoY, indicating a major deterioration in per-share results (often tied to share count changes, write-downs, or severe operating weakness).
Overall: financials do not support a high-conviction buy at this time.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target updates were provided; likely limited or no meaningful Street coverage.
Wall Street-style pros (inferred): any operational improvement or earnings surprise could move the stock sharply due to its small size.
Wall Street-style cons (inferred): lack of coverage/visibility, weak reported fundamentals (revenue ~0 and large losses), and a bearish technical structure reduce institutional-grade conviction.
Wall Street analysts forecast CDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDT is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDT is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
